MARKET

APGE

APGE

Apogee Therapeutics Inc
NASDAQ
38.14
-0.43
-1.11%
After Hours: 38.15 +0.01 +0.03% 19:45 07/11 EDT
OPEN
38.10
PREV CLOSE
38.57
HIGH
38.95
LOW
37.46
VOLUME
954.04K
TURNOVER
--
52 WEEK HIGH
63.50
52 WEEK LOW
26.20
MARKET CAP
2.27B
P/E (TTM)
-10.6343
1D
5D
1M
3M
1Y
5Y
1D
Apogee Therapeutics price target raised to $115 from $100 at BTIG
TipRanks · 1d ago
Apogee Therapeutics (APGE) Receives a Buy from BTIG
TipRanks · 1d ago
Stifel Nicolaus Reaffirms Their Buy Rating on Apogee Therapeutics (APGE)
TipRanks · 2d ago
3 Best Stocks to Buy Now, 7/9/2025, According to Top Analysts
TipRanks · 4d ago
Apogee Therapeutics: Funding Supports Best-In-Class Ambitions In Atopic Dermatitis
Seeking Alpha · 4d ago
Regeneron's Blockbuster Dupixent Faces a New Rival
Barron‘s · 4d ago
Gold Falls 1%; ProKidney Shares Spike Higher
Benzinga · 4d ago
Jefferies Sticks to Its Buy Rating for Apogee Therapeutics (APGE)
TipRanks · 4d ago
More
About APGE
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Rα. APG279 is for the dual inhibition of OX40L and IL-13.

Webull offers Apogee Therapeutics Inc stock information, including NASDAQ: APGE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APGE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APGE stock methods without spending real money on the virtual paper trading platform.